Dr Stefan Albrecht

Merz Therapeutics

Chief Scientific & Medical Officer

Board-certified neurologist with 25+ years of executive experience; at Merz since 2010, heading global R&D and medical functions.

Latest Company News

Merz bets on China Parkinson’s market with Kvvit licensing deal

2 June 2026

Merz Therapeutics names Dan Staner as president, Region Europe

2 February 2026

Acorda files for voluntary Chapter 11 Protection

3 April 2024

Merz splits into three with vow to target US medical aesthetics market

13 November 2019

FDA approves neurotoxin for excessive drooling in adults

4 July 2018

Merz nabs Allergan exec to head US neurosciences business

15 August 2017

Alzheimer's study finds 750% improvement with intensive program of care

17 July 2017

FDA approves new indication for Merz's Xeomin

24 December 2015

Copyright © The Pharma Letter 2026

| Headless Content Management with Blaze